Valor202020212022202320242025TTMGastos comerciales, generales y administrativos287.07 M378.33 M449.72 M506.45 M573.99 M663.42 M702.76 MInvestigación y desarrollo90.05 M104.55 M79.41 M84.42 M94.78 M89.77 M90.07 MBeneficio operativo-38.94 M-7.5 M6.08 M73.55 M9.28 M189.25 M187.13 MTotal de ingresos no operativos-343 K-4.44 M-5.53 M6.1 M11.59 M15.88 M15.82 MGastos por intereses, netos de intereses capitalizados1.52 M1.5 M1.44 M1.74 M1.42 M1.31 M1.31 MIngresos no operativos, una vez deducidos los gastos por intereses-1.52 M-2 M-4.64 M3.35 M12.27 M13.67 M15.17 MIngresos/gastos extraordinarios-343 K-3.94 M-2.33 M1.01 M-682 K893 K-652 KBeneficio antes de impuestos-38.02 M-10.5 M3.89 M79.65 M20.87 M205.13 M202.96 MParticipación en los beneficios0——————Impuestos-18.76 M-13.13 M5.89 M-11.3 M6.86 M27.44 M31.91 MParticipación minoritaria-3.56 M-2.66 M00———Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas-15.7 M5.28 M-2 M90.95 M14.01 M177.69 M171.05 MOperaciones suspendidas———————Beneficio neto-15.7 M5.28 M-2 M90.95 M14.01 M177.69 M171.05 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-15.7 M5.28 M-2 M90.95 M14.01 M177.69 M171.05 MBeneficio básico por acción-0.440.14-0.052.370.364.574.38Beneficio por acción diluido-0.440.14-0.052.320.364.524.34Número medio de acciones ordinarias35.77 M36.76 M37.84 M38.4 M38.63 M38.92 M—Acciones diluidas35.77 M37.88 M37.84 M39.22 M39.27 M39.29 M—EBITDA-26.05 M8.91 M30.4 M100.81 M32.98 M206.72 M204.16 MEBIT-38.94 M-7.5 M6.08 M73.55 M9.28 M189.25 M187.13 MCosto de los ingresos222.24 M272.21 M311.93 M375.88 M439.62 M461.23 M474.32 MOtros costes de producción10.57 M2.82 M3.44 M6.2 M43.66 M5.77 M4.92 MAmortización y depreciación (flujo de caja)12.89 M16.41 M24.32 M27.26 M23.7 M17.47 M17.03 M
Penumbra, Inc. Common Stock
Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.
In January 2026, Boston Scientific announced it would acquire Penumbra in a $15 billion cash and stock deal. The deal was expected to close by yearend.